This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
Bone Marrow Transplantation Open Access 30 January 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N . High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev 2013; (6): CD009411.
Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy. Haematologica 2012; 97: 1073–1079.
Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN et al. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1646–1652.
Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012; 119: 1665–1670.
Mocikova H, Pytlik R, Markova J, Steinerova K, Kral Z, Belada D et al. Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. Leuk Lymphoma 2011; 52: 1668–1674.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586.
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32: 3048–3058.
Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 2016; 374: 2419–2429.
Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010; 37: 1824–1833.
Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007; 109: 2481–2489.
Ansell SM, Armitage JO . Positron emission tomographic scans in lymphoma: convention and controversy. Mayo Clin Proc 2012; 87: 571–580.
Acknowledgements
Ethical standards statement: IRB approved the conduct of the study and waived the requirement for informed consent due to retrospective non-interventional study design. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.
Author contributions
Designed the study: MD. Collected data: MD and SG. Provided patients: all authors. Wrote and reviewed the manuscript: all authors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Damlaj, M., Ghazi, S., Syed, G. et al. Pre-autologous transplantation PET/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transplant 52, 1342–1344 (2017). https://doi.org/10.1038/bmt.2017.143
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2017.143
This article is cited by
-
Contemporary outcomes of high risk relapsed refractory classical hodgkin lymphoma patients—role of maintenance therapy in the real world
Bone Marrow Transplantation (2023)
-
Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma
Annals of Hematology (2023)
-
Role of Radiomics-Based Baseline PET/CT Imaging in Lymphoma: Diagnosis, Prognosis, and Response Assessment
Molecular Imaging and Biology (2022)
-
Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma
Bone Marrow Transplantation (2020)
-
Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
Bone Marrow Transplantation (2019)